TECFIDERA

Type: Keyphrase
Name: TECFIDERA
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

Biogen Idec Announces Strides In Clinical Studies For MS Treatments

By Lori ClapperBiogen Idec announced clinical study results for three of its Multiple Sclerosis (MS) treatments at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee ... [Published Bioresearch Online - Sep 18 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Biogen Idec and AbbVie report positive data from MS drug trial

:15 in Pharmaceutical Company Product News Biogen Idec and AbbVie have announced positive clinical trial data underlining the benefits offered by Zinbryta, their collaboratively-developed new treatment for multiple sclerosis (MS). Full results from the ... [Published Zenopa - Sep 17 2014]
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Biogen Idec announces encouraging data from Phase III multiple sclerosis study

Biogen Idec, a biotechnology company, has announced that five-year data from the ENDORSE Phase III extension study show TECFIDERA provides sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis, or RRMS. Across ... [Published Individual.com - Sep 17 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 4 reports

Dimethyl fumarate (Tecfidera) follow on study

11 September 2014Author:Results from a five year follow on study show dimethyl fumarate remained effective over that period and there was no increased risk of side effects. People who started treatment when newly diagnosed showed most benefit. Reported ... [Published Multiple Sclerosis Trust - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

How does tecfidera work

Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M.  Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.  J Clin Invest. 2014 1;124(5):2188-92. Taken orally, ... [Published Multiple Sclerosis Research - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 4 reports

Biogen's Phase 3 Tecfidera Trial Shows Positive 5-Year MS Data

Biogen Idec announced that five-year results from the ENDORSE Phase 3 extension study show Tecfidera (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting multiple sclerosis (RRMS). These ... [Published Drug Discovery and Development - Sep 11 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

ACTRIMS/ECTRIMS 2014 – Part 1

Update on oral therapies Gilenya Tecfidera Aubagio Drug vs. drug The annual congress of the European Committee on Treatment and Research in MS (ECTRIMS), held this year in conjunction with the Americas Committee (ACTRIMS), is the largest ... [Published MSology - Sep 11 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

NICE Recommends MS Drug Tecfidera

Biogen Idec said it will launch its multiple sclerosis drug Tecfidera within three months in England and Wales following a final coverage recommendation from the UK healthcare pricing watchdog.The National Institute for Health and Care Excellence recommended ... [Published FDA News - Sep 05 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 2 reports

NICE nod for Biogen’s MS drug after price reduction

Biogen Idec’s MS drug has been granted NICE approval following a price reduction, with the treatment available on a patient-access scheme across England and Wales.In final guidance recently released by the National Institute for Health and Care Excellence ... [Published Pharma Field - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 2 reports

NHS go ahead for new MS treatment

28th August 2014 – Multiple sclerosis patients in England and Wales will become eligible to receive the new medication dimethyl fumarate on the NHS by late November following final guidance from the National Institute for Health and Care Excellence ( ... [Published BootsWebMD - Aug 28 2014]
First reported Aug 27 2014 - Updated Aug 28 2014 - 5 reports

Biogen Idec's Tecfidera receives NICE recommendation

:07 in Pharmaceutical Company Product News Biogen Idec's new multiple sclerosis (MS) therapy Tecfidera has been approved for NHS use by the National Institute for Health and Care Excellence (NICE). In final guidance from the UK regulator, the dimethyl ... [Published Zenopa - Aug 28 2014]
First reported Aug 22 2014 - Updated Aug 22 2014 - 1 reports

New oral MS treatment Tecfidera approved for use in Northern Ireland

The Northern Ireland Health and Social Care Board has announced that Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in Northern Ireland. The Board reached its decision after reviewing the evidence on the ... [Published MS News - Aug 22 2014]

Quotes

...Gilmore O'Neill, vice-president for MS research and development at Biogen Idec, said: "If approved, Zinbryta would offer a novel mechanism to treating MS in a self-administered, once-monthly dosing regimen." This comes after another Biogen Idec MSMS therapy, Tecfidera, was approved for NHS use by the National Institute for Health and Care Excellence last...
...benefits and favorable safety profile," said Alfred Sandrock, M D , Ph D , group senior vice president and chief medical officer at Biogen Idec. "These new ENDORSE results provide further insight into the positive impact of using TECFIDERA early in the course of MS and for long-term treatment of this chronic disease."
"I'm confident in the U S approval and I'm confident in how the product will perform and be utilized" Genzyme's MS and neurology head Mike Panzara told the news service. "... The efficacy is just too good."

More Content

All (152) | News (86) | Reports (1) | Blogs (64) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Biogen Idec Announces Strides In Clinical Studi... [Published Bioresearch Online - Sep 18 2014]
Biogen Idec and AbbVie report positive data fro... [Published Zenopa - Sep 17 2014]
Biogen Idec announces encouraging data from Pha... [Published Individual.com - Sep 17 2014]
AbbVie, Biogen to file MS drug next year [Published Medical Marketing And Media - Sep 16 2014]
Biogen/AbbVie Report Positive Data on MS Drug Z... [Published Yahoo! Finance - Sep 15 2014]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
Making Treatment Decisions When There Is an Abu... [Published American Journal of Managed Care - Sep 14 2014]
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
AbbVie and Biogen inch toward the FDA with once... [Published FierceBiotech - Sep 12 2014]
Dimethyl fumarate (Tecfidera) follow on study [Published Multiple Sclerosis Trust - Sep 12 2014]
Pair of Multiple Sclerosis Drugs Produces Posit... [Published Pharmacy Times - Sep 12 2014]
Biogen: Still Leading The Multiple Sclerosis Ma... [Published Bidness Etc - Sep 12 2014]
Why Biogen Idec Inc's Stock is Up 17% in 2014 [Published Motley Fool - Sep 12 2014]
Strong and sustained efficacy reported for Tecf... [Published Pharma Letter - Sep 12 2014]
Dive in: gaining leadership in a therapeutic area [Published PMLive - Sep 12 2014]
JobWatch: Big Biopharma Drives Bay State Growth [Published Genetic Engineering News - Sep 12 2014]
How does tecfidera work [Published Multiple Sclerosis Research - Sep 12 2014]
Biogen's Phase 3 Tecfidera Trial Shows Positive... [Published Drug Discovery and Development - Sep 11 2014]
Sanofi keeps the faith in MS and eyes a new daw... [Published FierceBiotech - Sep 11 2014]
Biogen Idec's Phase 3 Study With Tecfidera Show... [Published RTTNews.com - Sep 11 2014]
Biogen Announces Five-Year Results from ENDORSE... [Published Benzinga.com - Sep 11 2014]
New Data from ENDORSE Show Positive Results Con... [Published Business Wire Health News - Sep 11 2014]
ACTRIMS/ECTRIMS 2014 – Part 1 [Published MSology - Sep 11 2014]
Sanofi aims to grow Genzyme unit with new drugs... [Published Reuters - Sep 11 2014]
Why Receptos Inc. Shares Rocketed Higher [Published Motley Fool Discussion Boards - Sep 10 2014]
Tips for Taking the Sting out of a $3K Deductible [Published Pharmacy Practice News - Sep 10 2014]
The top 10 best-selling multiple sclerosis drug... [Published FiercePharma - Sep 09 2014]
For multiple sclerosis sufferers, an anxious hope [Published Boston Globe - Sep 09 2014]
NICE Recommends MS Drug Tecfidera [Published FDA News - Sep 05 2014]
New Genzyme pill will cost patients $310 250 a ... [Published FirstWord Pharma - Sep 03 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
The regulators got it wrong and throw drug away [Published Multiple Sclerosis Research - Sep 13 2014]
J Pakpoor et al. Is there an increased cancer risk in people with relapsing multiple sclerosis taking cladribine? MS J Suppl The FDA/EMA saw a few cancers in the Movecro (oral cladribine) trial called CLARITY led by ProfG and wanted further trials ...
How does tecfidera work [Published Multiple Sclerosis Research - Sep 12 2014]
Chen H, Assmann JC, Krenz A, Rahman M, Grimm M, Karsten CM, Köhl J, Offermanns S, Wettschureck N, Schwaninger M.  Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.  J Clin Invest. 2014 1;124(5):2188-92. Taken orally, ...
New Data from ENDORSE Show Positive Results Con... [Published Business Wire Health News - Sep 11 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NEW DATA FROM ENDORSE SHOW POSITIVE RESULTS CONTINUED OVER FIVE YEARS WITH TECFIDERA® (DIMETHYL FUMARATE)IN A WIDE RANGE OF MULTIPLE SCLEROSIS PATIENTS ...
ACTRIMS/ECTRIMS 2014 – Part 1 [Published MSology - Sep 11 2014]
Update on oral therapies Gilenya Tecfidera Aubagio Drug vs. drug The annual congress of the European Committee on Treatment and Research in MS (ECTRIMS), held this year in conjunction with the Americas Committee (ACTRIMS), is the largest ...
New oral MS treatment Tecfidera approved for us... [Published MS News - Aug 27 2014]
Tecfidera (dimethyl fumarate) should be available for people with relapsing remitting MS in England and Wales, the National Institute for Health and Care Excellence ( NICE ) has announced.  The NHS must now begin funding this treatment for eligible ...
1 2 3 4 5 6 7 8 9 10 ...
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.